Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Otoact
- Development stage
- Unknown
- Lead developer
- Nextmune
- Modality
- Small Molecules
- Administration
- Otic, Topical
01
Overview
Otoact is a veterinary ear cleanser developed by Nextmune for use in dogs and cats. It is specifically formulated as a gentle ceruminolytic designed to dissolve excess earwax (cerumen) without irritating the ear canal. The product's primary active ingredient is squalene, a highly effective wax-dissolving agent, complemented by salicylic acid for its keratolytic and antiseptic properties. Additionally, it contains tannic acid as an astringent and Chamomilla recutita flower extract to provide soothing, anti-inflammatory relief to the ear lining. Otoact is used to maintain ear hygiene in companion animals prone to chronic wax buildup and as a supportive treatment for managing otitis externa.
- Brand names
- Otoact
02
Targets
Mpro (3C-like proteinase of SARS-CoV-2)TMPRSS2 (Transmembrane protease serine 2)
Beyond the preview
Go deeper on Otoact.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Otoact.